This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
Journal of Experimental & Clinical Cancer Research Open Access 03 May 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Lu, S. et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M + NSCLC: updated post NMPA-approval results from the APOLLO registrational trial. J. Thorac. Oncol. https://doi.org/10.1016/j.jtho.2021.10.024 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Aumolertinib is effective in NSCLC. Nat Rev Clin Oncol 19, 6 (2022). https://doi.org/10.1038/s41571-021-00586-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00586-x
This article is cited by
-
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
Journal of Experimental & Clinical Cancer Research (2022)
-
Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors
Frontiers of Medicine (2022)